Capital Impact Advisors, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Capital Impact Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $132,140 - $217,327	5,252 Added 34.06%	20,670 $737,000
Q1 2023 May 23, 2023	SELL	$23.68 - $38.51 $270,780 - $440,361	-11,435 Reduced 42.58%	15,418 $391,000
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $129,304 - $187,306	4,618 Added 20.77%	26,853 $1.09 Million
Q3 2022 Nov 21, 2022	BUY	$29.63 - $48.31 $82,697 - $134,833	2,791 Added 14.35%	22,235 $680,000
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $97,570 - $177,691	3,511 Added 22.04%	19,444 $685,000
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $477,024 - $842,438	12,040 Added 309.27%	15,933 $733,000
Q4 2021 Feb 14, 2022	BUY	$58.09 - $82.51 $226,144 - $321,211	3,893 New	3,893 $258,000
Q1 2021 May 18, 2021	SELL	$61.35 - $90.47 $5.41 Million - $7.98 Million	-88,183 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$43.82 - $85.37 $3.94 Million - $7.68 Million	-90,000 Reduced 50.51%	88,183 $6.77 Million
Q2 2020 Aug 17, 2020	BUY	$26.12 - $43.27 $2.45 Million - $4.05 Million	93,646 Added 110.78%	178,183 $7.7 Million
Q1 2020 May 15, 2020	BUY	$20.56 - $63.12 $1.74 Million - $5.34 Million	84,537 New	84,537 $2.43 Million

295

91.1M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.23B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.